ArticleEndocrine1995
Fibroblast growth factor enhances expression of TGFβ-stimulated-clone-22 gene in osteoblast-like cells.
Article in Endocrine, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transforming growth factor-β1 (TGFβ1)-stimulated clone 22 (TSC-22) is a primary response gene isolated by subtractive screening of genes expressed in murine osteoblastic cells treated with TGFβ1, which is one of the cytokines abundantly stored in bone. Fibroblast growth factor (FGF) is also stored in bone matrix and acts as a potent autocrine/paracrine modulator of osteoblastic function. In this report, we investigated FGF effects on the expression of TSC-22 gene in a murine osteoblast-like cell line, MC3T3E-1. Treatment with recombinant basic FGF enhanced TSC-22 mRNA level in these cells within 1 h. This effect peaked at 2 h with several fold enhancement, after which the mRNA abundance returned to the basal level by 24 h. The FGF effect was dose-dependent, starting at 0.2 ng/ml, peaking at 2 ng/ml, and then declining at 20 ng/ml. The FGF effect on TSC-22 mRNA was blocked by actinomycin D, indicating the involvement of transcriptional events. The FGF enhancement of TSC-22 mRNA expression was partially blocked by genistein. Additive effect was observed upon contreatment with saturating concentrations of FGF and TGFβ, suggesting the presence of at least two independent pathways for the two cytokines in the regulation of TSC-22 gene expression. These results indicate that the TSC-22 gene is one of the targets of FGF action in osteoblasts.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.